Biobanks in Spain. An overview.
|
|
- Sandra Carter
- 6 years ago
- Views:
Transcription
1 Biobanks in Spain. An overview. ENRIQUE DE ALAVA UNIVERSIDAD DE SALAMANCA-CSIC Salamanca, Spain
2 BIOMEDICINE AND HEALTH CARE ENVIRONMENT INHERITED GENES LIFESTYLE GENOME PROTEOME
3 BIOMEDICINE AND HEALTH CARE ENVIRONMENT INHERITED GENES LIFESTYLE GENOME PROTEOME TREATMENT HEALTH DISEASE RESISTANCE SENSITIVITY PERSONALISED MEDICINE
4 BIOBANK -An establishment that manages -A collection of biological samples- -Plus clinical information -Organized as a service -With a clear design, and quality ethical criteria -For biomedical research.
5 BIOBANK -An establishment that manages -A collection of biological samples- -Plus clinical information -Organized as a service -With a clear design, and quality ethical criteria -For biomedical research.
6 Biobank aims To obtain, process and store biological samples and their associated data. To provide samples to research groups. To ensure a rational, effective, ethical and legal use of the available resources.
7 Structure of a Biobank External Scientific Committee External Committee on Ethics Metabolic diseases Cardiovascular diseases CENTRAL NODE Oncological diseases Neuropsychiatric diseases ASSOCIATED CENTERS RESEARCH GROUPS
8 SPANISH LAW ON BIOMEDICAL RESEARCH: requisits for a biobank - Authorized by the regional governments ( National Registry to be created by the Ministry of Science) - Structure of the organization: - Activities: - Scientific director & person responsible for database - External Committees - To ensure fulfilling all legal requirements - Registry of activities - Guarantee of quality, safety & traceability of samples, data y procedures - Respond to enquires & claims - Good-practice manual/documentation - Annual report
9 The actual value of a biobank lies on the existence of cooperative research projects of excellence. Design an action plan before creating a biobank
10 Outline Biobanks in Spain Why What for Network of biobanks National Biobanks Towards National Hubs of clinical biobanks What else
11 Outline Biobanks in Spain Why What for Network of biobanks National Biobanks Towards National Hubs of clinical biobanks What else
12 Translational research
13 How Biobanks (tumor banks) are Key to Translational research in Molecular Pathology of Cancer?
14 How tumor banks are Assess new predictive factors Assess the value of a known target in a new entity Look for new therapeutic targets Validation of a new diagnostic marker Implementation of new diagnostic procedures
15 How tumor banks are Assess new predictive factors Assess the value of a known target in a new entity Look for new therapeutic targets Validation of a new diagnostic marker Implementation of new diagnostic procedures
16 How tumor banks are Assess new predictive factors Assess the value of a known target in a new entity Look for new therapeutic targets Validation of a new diagnostic marker Implementation of new diagnostic procedures
17 How tumor banks are Assess new predictive factors Assess the value of a known target in a new entity Look for new therapeutic targets Validation of a new diagnostic marker Implementation of new diagnostic procedures
18 How tumor banks are Assess new predictive factors Assess the value of a known target in a new entity Look for new therapeutic targets Validation of a new diagnostic marker Implementation of new diagnostic procedures
19 Outline Biobanks in Spain Why What for Network of biobanks National Biobanks Towards National Hubs of clinical biobanks What else
20 Outline Biobanks in Spain Why What for Network of biobanks National Biobanks Towards National Hubs of clinical biobanks What else
21
22
23
24 Regional networks, 2009 Redes en desarrollo: Castilla-León Cataluña Andalucía Asturias Red promovida por el CNIO: Madrid Canarias Galicia Hasta 21 Centros de 8 CCAA. 6 hospitales no asociados en ninguna red territorial.
25 CNIO Network Red CNIO: 24 Centros de 9 CCAA. Madrid Canarias Galicia Baleares Fuente:
26 Tumor banks (Jan 2009) Regional: Castilla y León Cataluña Andalucía Asturias CNIO: 24 Centros de 9 CCAA. Madrid Canarias Galicia Other networks.
27 Quality of tissue fixation (for tissue microarray) VIMENTIN WEAK 13% CD 31 MIB1 OK 87% WEAK 16% NEGATIVE 3% RESULTS KI-67 (MIB-1) NEGATIVE 9% WEAK 28% OK 81% Vimentin CD31 OK 63%
28 Quality of RNA (for DNA arrays) RNA DEGRADATION MODERATE 3% NON ASSESSABLE 3% WEAK 9% OK 85% Ratio 260/ % < 1.8 > 2.2
29 Papers in peer-review journals with explicit reference to biobanks ,00 Number: 99 Median IF: 7,256 8,00 7,00 6,00 5,00 4,00 3,00 2,00 1, ,
30 Projects assisted by the Tumor Bank Network : : : : :
31 Outline Biobanks in Spain Why What for Network of biobanks National Biobanks Towards National Hubs of clinical biobanks What else
32 Outline Biobanks in Spain Why What for Network of biobanks National Biobanks Towards National Hubs of clinical biobanks What else
33
34 National DNA Bank of Spain STRUCTURE Central Node Coordinating center: Universidad de Salamanca Director: Dr. Alberto Orfao Oncological Node Coordinating center: Centro de Investigación del Cáncer (Salamanca) Coordinator: Dr. Enrique de Álava Cardiovascular Node Coordinating center: Fundación IMIM (Barcelona) Coordinator: Dr. Jaume Marrugat Metabolic Node Coordinating center: IDIBAPS-Hospital Clinic (Barcelona) Coordinator: Dr. Ramón Gomis Neuropsychiatric Node Coordinating center: Institut d Investigació Sanitària Pere Virgili (IISPV) (Reus) Coordinator: Dra. Elisabet Vilella Regional Blood Transfusion Centers Consejería de Sanidad JCyL Hospital Vall d Hebron Centro de Estudios de Mastocitosis de Castilla la Mancha Foundations for Fibromialgy and Chronic Fatigue Syndrome
35 BNADN: AVAILABLE SAMPLES (2008) Control population: N.of samples Cell lines - Spanish population - Population of Castilla y León - Nonagenarians 30 Prevalent diseases: Neuropsychiatric diseases Metabolic diseases Cardiovascular diseases Oncological diseases Other diseases: - Fibromialgy and Chronic Fatigue Syndrome Mastocytosis Immune-mediated inflammatory diseases and controls Total:
36 National DNA Bank, node on oncological diseases
37 National DNA Bank, node on oncological diseases Colorectal ca. Breast ca. Lung ca. Head&neck ca. NHL Acute leukemia CLL Chronic MP syndrome Frozen tissue Cells Plasma/serum 500 patients of each Clinical data Epidemiological data Follow up data
38 Outline Biobanks in Spain Why What for Network of biobanks National Biobanks Towards National Hubs of clinical biobanks What else
39 Outline Biobanks in Spain Why What for Network of biobanks National Biobanks Towards National Hubs of clinical biobanks What else
40 European Research Infrastructure Bio- Banking and Biomolecular Resources ROADMAP PROPOSAL FOR D.3.7.: CONCEPT FOR NATIONAL HUBS OF CLINICAL BIOBANKS
41 DELIVERABLE 3.7.: CONCEPT FOR NATIONAL HUBS OF CLINICAL BIOBANKS AIM To generate a concept on how to integrate clinical biobanks in Europe in national hubs.
42 DELIVERABLE 3.7.: CONCEPT FOR NATIONAL HUBS OF CLINICAL BIOBANKS NATIONAL HUBS Austria Germany Greece Finland France Hungary Italy Netherl. Spain UK Cardiovascular Metabolic Neuropsychiatric Oncologic Orphan diseases? Respiratory Allergy
43 DELIVERABLE 3.7.: CONCEPT FOR NATIONAL HUBS OF CLINICAL BIOBANKS Country A Disease C NATIONAL HUBS
44 DELIVERABLE 3.7.: CONCEPT FOR NATIONAL HUBS OF CLINICAL BIOBANKS Country A Disease C NATIONAL HUBS Cordina tor
45 DELIVERABLE 3.7.: CONCEPT FOR NATIONAL HUBS OF CLINICAL BIOBANKS NATIONAL HUBS Country A Disease B Country A Disease C Country A Disease D
46 DELIVERABLE 3.7.: CONCEPT FOR NATIONAL HUBS OF CLINICAL BIOBANKS NATIONAL HUBS Country A Disease B Country A Disease C Country A Disease D National Coordin
47 DELIVERABLE 3.7.: CONCEPT FOR NATIONAL HUBS OF CLINICAL BIOBANKS IDENTIFICATION OF BIOBANKS CARDIOVASCULAR METABOLIC NEUROLOGIC CANCER I. M. I. D. ALLERGIC RARE DISEASES DNABank (R. Gomis) DNABank (E. Vilella) DNABank/RTICC Tumor Bank Network (E. de Alava) DNABank SPAIN DNABank (J. Marrugat) (S. Marsal) Research Network on Allergy (M. Blanca) CIBERER (F. Palau) AUSTRIA
48 DELIVERABLE 3.7.: CONCEPT FOR NATIONAL HUBS OF CLINICAL BIOBANKS NATIONAL HUBS Country A Disease B Country A Disease C Country A Disease D National Coordin Country B Disease B National Coordin Country B Disease A Country B Disease D
49 DELIVERABLE 3.7.: CONCEPT FOR NATIONAL HUBS OF CLINICAL BIOBANKS NATIONAL HUBS Country A Disease B Country A Disease C Country A Disease D Disease Coordin National Coordin Disease Coordin Country B Disease B National Coordin Disease Coordin Disease Coordin Country B Disease A Country B Disease D
50 DELIVERABLE 3.7.: CONCEPT FOR NATIONAL HUBS OF CLINICAL BIOBANKS NATIONAL HUBS Country A Disease B Country A Disease C Country A Disease D Disease Coordin National Coordin Disease Coordin Country B Disease B National Coordin Disease Coordin Disease Coordin Country B Disease A Country B Disease D
51 DELIVERABLE 3.7.: CONCEPT FOR NATIONAL HUBS OF CLINICAL BIOBANKS NATIONAL HUBS Country A Disease B Country A Disease C Country A Disease D Country B Disease B -Clinical Phenotypes -Typesofsamples Disease Coordin National Coordin Ethical/legal (ELSI) frame National Coordin Disease Coordin -Clinical Phenotypes -Typesofsamples Disease Coordin Disease Coordin Country B Disease A Country B Disease D
52 DELIVERABLE 3.7.: CONCEPT FOR NATIONAL HUBS OF CLINICAL BIOBANKS PROPOSAL FOR A NATIONAL HUB ADVISORY BOARDS coordinating centre NATIONAL CONTACT DISEASE NODE 1 DISEASE NODE 2 DISEASE NODE 3 DISEASE NODE X
53 KEY POINTS Coordinating Centre: National contact: scientific management Common data-base (information in samples/data available, ) Quality control (common-harmonized- SOPs, minimal data set, ) Responsible of QMS Disease nodes: Coordinating node: Scientific board: defining common diagnostic criteria (international standards), minimal clinical data, Subnodes: institutional (hospital) based biobanks Centralized vs decentralized sample/data process Advisory board: Representatives of legal entities, funding agencies, directorate, coordinators of disease nodes
54
55
56
57
58 Outline Biobanks in Spain Why What for Network of biobanks National Biobanks Towards National Hubs of clinical biobanks What else
59 Outline Biobanks in Spain Why What for Network of biobanks National Biobanks Towards National Hubs of clinical biobanks What else
60 Scientific/health care questions: Questions Better organizative protocols to better face the increment of numbers of tissue requests (translational research, bioinformatics). Better sample selection, preparation and storage. Which sample types to collect (just tumours?, normal blood?, tumour DNA as well?, plasma/serum of tumour patients?). Which storage formats (just snap frozen?, cell suspensions?) Quality of the process. Developing standards, SOPs, which ISO certifications?. Who should have access to the samples?, to which samples?, how?. Private-for-profit institutions?. The role of a scientific committee. Definitions and normalisation systems for diagnosis and topographical information to guarantee uniformity of pathological annotation, (CIE-9?, SNOMED?),... Role of the tumour banks in the development of new drugs. Central unit?, intermediate partner between industry and oncologists?. Intellectual property.
61 Questions Information technology How to identify/label samples in a European perspective. Quality of the data and standards. Data integration (clinical, pathological, epidemiological, relationship with tumour registries). Data protection and database safety. Managing knowledge.
62 Questions Questions on ethics-law-funding-social Towards a European Legal framework. Ownership of tumour banks. How to finance tumour banks. Who?. The role of Ethics committees.
63 Outline Biobanks in Spain Why What for Network of biobanks National Biobanks Towards National Hubs of clinical biobanks What else
64 Outline Biobanks in Spain Why What for Network of biobanks National Biobanks Towards National Hubs of clinical biobanks What else
65 Gracias! Gracias!
66 BIOBANKS AND TRANSLATIONAL RESEARCH SAMPLE BIOBANK MOLECULAR TRANSLATIONAL RESEARCH ANALYSIS PATIENT LABORATORY DIAGNOSTIC & THERAPEUTICS MARKERS MOLECULAR PROFILING EXPERIMENTAL RESULTS
Plataformas de apoyo a la investigación: biobancos y centros de recursos biológicos
Plataformas de apoyo a la investigación: biobancos y centros de recursos biológicos Jornadas: La realidad de los biobancos a la luz del nuevo marco normativo: retos e implicaciones Centro de Investigación
More informationArto Mannermaa. Research Manager, KUH Professor of personalized medicine and Biobanking, UEF
Doctoral Programme of Clinical Research Introduction to Clinical Research, 2017 Arto Mannermaa Research Manager, KUH Professor of personalized medicine and Biobanking, UEF 040-3552752 arto.mannermaa@uef.fi
More informationROUND TABLE ARISLA Milano 26 marzo 2014 Le BioBanche Nodo Italiano di Biobanking and Biomolecular Resources Research Infrastructure
ROUND TABLE ARISLA Milano 26 marzo 2014 Le BioBanche Nodo Italiano di Biobanking and Biomolecular Resources Research Infrastructure Marialuisa Lavitrano Università Milano-Bicocca Coordinatore BBMRI-Italia
More informationBiomedical Network Research Centre on Rare Diseases
Biomedical Network Research Centre on Rare Diseases A model of cooperative research on Rare Diseases ICORD 2010 Prof. Francesc Palau Scientific Director of CIBERER Instituto de Biomedicina, CSIC, Valencia,
More informationA Gateway for Health: BBMRI and Africa Prof. Jan-Eric Litton Director General BBMRI-ERIC
A Gateway for Health: BBMRI and Africa Prof. Jan-Eric Litton Director General Most of our current knowledge on diseases as well as available diagnostic assays and drugs are based on investigation of biological
More informationFor more information about the final programme, speakers or the EHFG conference please contact us directly!
For more information about the final programme, speakers or the EHFG conference please contact us directly! SAVE THE DATE! 18th EHFG: 30 September 02 October 2015 EHFG-FORUM 4 PERSONALISED MEDICINE 2020
More information17th EHFG Electing Health The Europe We Want!
01 03 October 2014 17th EHFG Electing Health The Europe We Want! For more information about the final programme, speakers or the EHFG conference please contact us directly! Follow us on our social media
More informationWhat to collect and is it fit for purpose?
What to collect and is it fit for purpose? Gerry Thomas, Professor of Molecular Pathology, Imperial College, London Scientific Director, Wales Cancer Bank The pragamatic approach... What do the studies
More informationBBMRI.NL A story of Sharing Eline Slagboom Molecular Epidemiology, Leiden University Medical Center Brussel 20 Juni 2017
BBMRI.NL A story of Sharing Eline Slagboom Molecular Epidemiology, Leiden University Medical Center Brussel 20 Juni 2017 BBMRI-NL TOWARDS A NATIONAL BIOBANKING INFRASTRUCTURE Founded in 2009 as the Dutch
More informationFinnish Biobanks. The most advanced testbed in the world
Finnish Biobanks The most advanced testbed in the world Jaana Hartikainen, Ph.D., Adjunct Professor in Molecular Genetics Assistant Professor in Translational Cancer Research and Biobank Research University
More informationBiomarker Regulation. Regulator s perspective. Jan Müller-Berghaus
www.pei.de Biomarker Regulation Regulator s perspective Jan Müller-Berghaus The views presented here are my own and do not necessarily reflect the views of the Paul-Ehrlich-Institut or any other regulatory
More informationThe 100,000 Genomes Project Genomics Collaboration Event Finnish Residence
The 100,000 Genomes Project Genomics Collaboration Event Finnish Residence Prof Mark Caulfield FMedSci Chief Scientist for Genomics England Barts Heart Centre William Harvey Research Institute Queen Mary
More informationAll research lines at the LMU have a strong methodological focus
Content: Genetic Epidemiology and Statistical Genetics in Complex Diseases... 2 Molecular Epidemiology of Complex Phenotypes... 2 Clinical Trials and Translational Medicine... 3 Clinical Epidemiology and
More informationGenetics/Genomics in Public Health. Role of Clinical and Biochemical Geneticists in Public Health
Genetics/Genomics in Public Health Role of Clinical and Biochemical Geneticists in Public Health Premises Human variation is vast Strength of genetic factors are a continuum from low to high Testing technology
More informationBIG DATA: from the Moli-sani project to the Neuromed integrated health platform and Biobank
BIG DATA: from the Moli-sani project to the Neuromed integrated health platform and Biobank Maria Benedetta Donati Giovanni de Gaetano and Licia Iacoviello Department of Epidemiology and Prevention IRCCS,
More information- OMICS IN PERSONALISED MEDICINE
SUMMARY REPORT - OMICS IN PERSONALISED MEDICINE Workshop to explore the role of -omics in the development of personalised medicine European Commission, DG Research - Brussels, 29-30 April 2010 Page 2 Summary
More information1.0 Background to the organisation
1.0 Background to the organisation The National University of Ireland Galway, the Royal College of Surgeons in Ireland, University College Cork, University College Dublin and Trinity College and their
More informationPrecision Medicine. Presented by:
Precision Medicine Presented by: Prepared Brendan FitzGerald For: Enabling better health through information technology. Healthcare Information and Management Systems Society (HIMSS) HIMSS is a global,
More informationGUIDANCE ON THE EVALUATION OF NON ACCREDITED QUALIFICATIONS
GUIDANCE ON THE EVALUATION OF NON ACCREDITED QUALIFICATIONS 1. Introduction 1.1 This document provides guidance notes for the assessment of academic qualifications that have not been formally accredited
More informationTopic: Genome-Environment Interactions in Inflammatory Skin Disease
Topic: Genome-Environment Interactions in Inflammatory Skin Disease All information regarding future IMI Call topics is indicative and subject to change. Final information about future IMI Calls will be
More informationOverview of the Luxembourg biomedical and health research ecosystem FNR FRANK GLOD LUXCOR HEALTH EVENT MONDAY 19 JUNE 2017
FNR Overview of the Luxembourg biomedical and health research ecosystem FRANK GLOD LUXCOR HEALTH EVENT MONDAY 19 JUNE 2017 Research in Luxembourg Luxembourg : a young research location Creating structures
More informationCIBIR: Center for Biomedical Research of La Rioja Eduardo Mirpuri, PhD. Biomedical Research Coordinator
FP7 Health Partnering event 10 June 2011, Brussels International session CIBIR: Center for Biomedical Research of La Rioja Eduardo Mirpuri, PhD. Biomedical Research Coordinator Translational Research CIBIR:
More informationChildren s health and the environment
Organised by ARTAC in partnership with ISDE and HEAL Third Paris Appeal International Congress Children s health and the environment Intensive Course in Environmental Medicine April 14, 15 and 16, 2011
More informationIBBL: Introduction to Biobanks and their services
IBBL: Introduction to Biobanks and their services HighTech meets Health, Oss (NL), 15 th June 2017 Monica Marchese, PhD Biomarker Validation Scientist AN ACCREDITED & CERTIFIED BIOBANK INFRASTRUCTURE FOR
More informationThe Innovative Medicines Initiative. Pierre Meulien CNIO, Madrid - Spain
The Innovative Medicines Initiative Pierre Meulien 12.01.2017 CNIO, Madrid - Spain IMI Europe s partnership for health > 5 bn 2.5 bn Partnership 2008-2020 Pharma industry 2.5 bn EU contribution from FP7
More informationVision, aims and strategies. Department of Immunology, Genetics and Pathology Uppsala University
Vision, aims and strategies Department of Immunology, Genetics and Pathology Uppsala University April19,2011 SCOPEOFACTIVITIESATIGP Research at the Department focuses on translational medicine through
More informationSPANISH NATIONAL BIOBANK NETWORK
Doc 10/01-eng SPANISH NATIONAL BIOBANK NETWORK Strategic Plan mmorente CNIO The Strategic Plan 2010-2013 of the Spanish National Biobank 10/01/2010 Network was approved by the network Plenary Board and
More informationData representation for clinical data and metadata
Data representation for clinical data and metadata WP1: Data representation for clinical data and metadata Inconsistent terminology creates barriers to identifying common clinical entities in disparate
More informationCOLORECTAL CANCER 1 EARLY-ONSET INTERNATIONAL SYMPOSIUM. MADRID 6th JUNE
1 EARLY-ONSET st 6th JUNE Venue: Hospital Universitario Fundación Jiménez Díaz. Aula Magna. Av. de los Reyes Católicos 2, Madrid Scientific Coordinators: Organized by: Dr. José Perea García Hospital Universitario
More informationCOLORECTAL CANCER. 1 st EARLY-ONSET INTERNATIONAL SYMPOSIUM. MADRID 6 th JUNE. Venue: Organized by: Scientific Coordinators:
Venue: Hospital Universitario Fundación Jiménez Díaz - Aula Magna - Av. de los Reyes Católicos 2, Madrid Scientific Coordinators: Dr. José Perea García Hospital Universitario Fundación Jiménez Díaz, Madrid
More informationThis document is a preview generated by EVS
TECHNICAL SPECIFICATION SPÉCIFICATION TECHNIQUE TECHNISCHE SPEZIFIKATION CEN/TS 16827-2 August 2015 ICS 11.100.10 English Version Molecular in vitro diagnostic examinations - Specifications for pre-examination
More informationSpanish Paediatric Clinical Trials Network (RECLIP)
Spanish Paediatric Clinical Trials Network (RECLIP) Enpr-EMA Annual meeting 2017 (London) Cristina Serén Trasorras Operational Manager of RECLIP Spanish Paediatric Clinical Trials Network RECLIP, formally
More informationEATRIS ERIC Supporting translational research for better patient outcomes
EATRIS ERIC Supporting translational research for better patient outcomes II CONFERENCIA H2020 Y SALUD Anton Ussi Operations Director antonussi@eatris.eu What is translational research? the process of
More informationMRC Stratified Medicine Initiative
MRC Stratified Medicine Initiative Jonathan Pearce Medical Research Council, Translational Programme Manager Pharmacogenetics and Stratified Medicine Network Conference : 14 th January 2015 Stratified
More informationThe road to the future: biomedical research paving the way towards precision medicine
The road to the future: biomedical research paving the way towards precision medicine Conference 24-25 November 2016 Celebrating 15 years of Biomedical Research at Eurac Eurac Research, Center for Biomedicine,
More informationMolecular Diagnostics
Molecular Diagnostics Part II: Regulations, Markets & Companies By Prof. K. K. Jain MD, FRACS, FFPM Jain PharmaBiotech Basel, Switzerland May 2018 A Jain PharmaBiotech Report A U T H O R ' S B I O G R
More informationEconomic Impact. IWGSC March 12, Jim Vaught, Ph.D. Jim Vaught, Ph.D. Deputy Director. ESBB Marseille November 2011
ESBB Marseille November 2011 Biospecimen Collections: Biobank Economic Business Issues Planning and Economic Impact IWGSC March 12, 2009 Jim Vaught, Ph.D. Deputy Director Jim Vaught, Ph.D. November 5,
More informationThe Irish Biomarker Network - Inaugural Workshop Improved Translation of Biomarkers to the Clinic
The Irish Biomarker Network - Inaugural Workshop Improved Translation of Biomarkers to the Clinic 1 The Irish Biomarker Network -Inaugural Workshop Improved Translation of Biomarkers to the Clinic Overview
More informationData Mining for Genomic- Phenomic Correlations
Data Mining for Genomic- Phenomic Correlations Joyce C. Niland, Ph.D. Associate Director & Chair, Information Sciences Rebecca Nelson, Ph.D. Lead, Data Mining Section City of Hope National Medical Center
More informationA whole-system approach to delivering personalised medicine and health in Leeds. Mike Messenger
A whole-system approach to delivering personalised medicine and health in Leeds Mike Messenger Capacity and Resource What is the challenge? In 2016, we face the most significant challenges for a generation.
More informationTRANSLATIONAL RESEARCH IN RARE AND NEUROMUSCULAR DISEASES - WHY DATA SHARING MATTERS. H a n n s Lochmüller, Newcastle University
TRANSLATIONAL RESEARCH IN RARE AND NEUROMUSCULAR DISEASES - WHY DATA SHARING MATTERS H a n n s Lochmüller, Newcastle University Addressing the translational pathway 2 Trials Gene identification/ pathophysiology
More informationExamples of best practices for capacity building in Africa. Dr Maimuna Mendy, Head LSB Group (LSB/DIR) ibb.iarc.fr bcnet.iarc.
Biobanking collaboration with Africa: BBMRI-ERIC s contribution to health research capacity building in Africa, Wednesday, 5 April 2017 COMECE - Square de Meeûs, 19, B-1050 Brussels, Belgium Examples of
More informationLe banche dei tessuti
Le banche dei tessuti Rete Oncologica del Piemonte e della Valle d Aosta: Le ricerche e realizzazioni negli anni 2008-2009 12 Maggio 2010 GIORGIO INGHIRAMI Department of Biomedical Science and Human Oncology
More informationAsterand Bioscience Strategic Alliances
Asterand Bioscience Strategic Alliances Excellence through partnership www.asterandbio.com WHY ASTERAND BIOSCIENCE Asterand Bioscience has a well-established human tissue heritage, having been formed in
More informationAdvancing utility and adoption of clinical genomic diagnostics
Advancing utility and adoption of clinical genomic diagnostics Laura J. van t Veer Director Applied Genomics, Program Leader Breast Oncology Helen Diller Family Comprehensive Cancer Center University of
More informationInnovative Medicines Initiative (IMI) Future funding opportunities. Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017
Innovative Medicines Initiative (IMI) Future funding opportunities Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017 Outline What is IMI and why do we need it? How does IMI work?
More information20/12/2013 HERACLES. KICK-OFF meeting Dec The EC launched a SPECIFIC CALL (First Time!!) on the neglected infectious diseases.
HERACLES KICK-OFF meeting 17-18 Dec 2013 The EC launched a SPECIFIC CALL (First Time!!) on the neglected infectious diseases. 1 THEME: HEALTH.2013.2.3.4-1: Neglected infectious diseases of Central and
More informationProposal of Recommendations for a National Personalised Precision Medicine Strategy
1st ICPerMed Conference: Personalised Medicine in Action ICPerMed AWARD 2018 "Best Practice in Personalised Medicine National Personalised Precision Medicine Strategy Consuelo Martin de Dios Managing Director
More informationAnnex VIIIB Paragraphs to be included in the Informed Consent Form for the collection and use of biological samples in clinical trials
DEPARTAMENTO DE MEDICAMENTOS DE USO HUMANO Annex VIIIB Paragraphs to be included in the Informed Consent Form for the collection and use of biological samples in clinical trials Version 20 th December
More informationGenomic Medicine for the University of Vermont Health Network
Genomic Medicine for the University of Vermont Health Network The heart and science of medicine. Debra G.B. Leonard, M.D., Ph.D. Chair & Professor, Pathology & Laboratory Medicine Robert Larner, M.D. College
More informationBBMRI.at. Biobanking and BioMolecular resources Research Infrastructure Austria
THE AUSTRIAN NODE of the European Biobanking and BioMolecular resources Research Infrastructure BBMRI-ERIC Biobanking and BioMolecular resources Research Infrastructure Austria 3 BACKGROUND The impact
More informationThe EORTC Molecular Screening programme SPECTA
The EORTC Molecular Screening programme SPECTA February 2016 Denis Lacombe, MD, MSc EORTC, Director General Brussels, Belgium The changing shape of clinical research Phase I RESOURCES Phase III The changing
More informationMadrid, 26/03/2012 Marta Gómez Quintanilla IMI & Health Spanish Representative EU s R&D Framework Programme Department
Madrid, 26/03/2012 Marta Gómez Quintanilla IMI & Health Spanish Representative EU s R&D Framework Programme Department 1 (27/03/2012) Índice Spanish participation & results 1st call & 2nd call statistics
More informationDe la Investigación al Mercado Farmacéutico: Mecanismos de actuación y elementos tractores
De la Investigación al Mercado Farmacéutico: Mecanismos de actuación y elementos tractores Raúl Martín-Ruiz, PhD Sevilla, September 26 2018 Contents 01 From Academic Science to Product 02 What do we have
More informationBridging the Gap Between Basic and Clinical Research. Julio E. Celis Danish Cancer Society
Bridging the Gap Between Basic and Clinical Research Julio E. Celis Danish Cancer Society Barriers and Oportunities in Translational Research Promise of the new technologies What is Europe doing? Challenges
More information3ª MESA: QUÉ UTILIDAD OFRECE EL BIG DATA?
3ª MESA: QUÉ UTILIDAD OFRECE EL BIG DATA? Jesús M. Hernández Rivas Instituto de Investigación Biomédica de Salamanca. Universidad de Salamanca. Servicio de Hematología. Hospital Universitario de Salamanca.
More informationE O. The EORTC Strategy for New Drug Development THE EORTC PROVIDES: The EORTC is the leading pan-european partner for high-quality clinical research
The EORTC Strategy for New Drug Development The EORTC is the leading pan-european partner for high-quality clinical research E O RT C THE EORTC PROVIDES: A NETWORK OF HIGH-QUALITY, DEDICATED CLINICAL RESEARCHERS
More informationPersonalized. Health in Canada
Personalized Health in Canada Canadian Institutes of Health Research Personalized Medicine Signature Initiative 2010-2013 0 Dr. Morag Park CIHR Institute of Cancer Research Dr. Paul Lasko CIHR Institute
More informationOECI WORKING GROUP HIGHLIGHTS
OECI WORKING GROUP HIGHLIGHTS Pathobiology Mission Statement To create European (molecular) pathology based platforms or environments that enable or improve knowledge transfer and translational research
More informationBOARD PAPER - NHS ENGLAND. Purpose of Paper: To inform the Board of the development of an NHS England Personalised Medicine Strategy.
Paper: PB.24.09.15/05 Title: Personalised Medicine Strategy. From: Sir Bruce Keogh, National Medical Director. BOARD PAPER - NHS ENGLAND Purpose of Paper: To inform the Board of the development of an NHS
More informationThe monthly change of the Retail Trade Index at constant prices stands at 0.9% after adjusting for seasonal and calendar effects
29 September 2016 Retail Trade Indices (RTI). Base 2010 August 2016. Provisional data The monthly change of the Retail Trade Index at constant prices stands at 0.9% after adjusting for seasonal and calendar
More informationChallenges of Personalized Health for Clinical Medicine. Peter J Meier-Abt Swiss Academy of Medical Sciences (SAMS) Berne, Switzerland
Challenges of Personalized Health for Clinical Medicine Peter J Meier-Abt Swiss Academy of Medical Sciences (SAMS) Berne, Switzerland Personalisierte Medizin Personalisierte Gesundheit Personalisierte
More informationTHE CELL BIOLOGY BEHIND THE ONCOGENIC PIP3 LIPIDS
WORKSHOPS CURRENT TRENDS IN BIOMEDICINE 2018 SEDE ANTONIO MACHADO BAEZA, SPAIN THE CELL BIOLOGY BEHIND THE ONCOGENIC PIP3 LIPIDS Baeza, Spain 15 th -17 th October 2018 Organized by: Ana C. Carrera Richard
More informationThe monthly change of the Retail Trade Index at constant prices stands at 0.1% after adjusting for seasonal and calendar effects
28 June 2018 Retail Trade Indices (RTI). Base 2015 May 2018. Provisional data The monthly change of the Retail Trade Index at constant prices stands at 0.1% after adjusting for seasonal and calendar effects
More informationForthcoming Calls for Proposals (10/11) Barcelona 28 June 2013
Forthcoming Calls for Proposals (10/11) Barcelona 28 June 2013 Indicative list Proposed topic /11 /11 /11 Identification and validation of innovative clinical endpoints for Osteoarthritis European genotype-phenotype
More informationBGEN Laboratory Methods in Human and Medical Genetics
BMG COURSES BGEN 7000 - Research Seminar MSc Consists of presentations of the student's current research. For Master s students only. 1.0 credit hours. BGEN 7020 Proteins (Formerly 137.702) Three hours
More informationPERSONALIZED CANCER CARE
Translational Research Promises to Advance Molecular Medicine for Cancer Patients Molecular Data Diagnosis / Therapy PERSONALIZED CANCER CARE Biospecimen Distribution Biospecimen Collection Biospecimen
More informationThe experience of Andalusia in ehealth and big data --- Big data in health - IMI s HARMONY project, European Parliament, Brussels, 19 June 2018
The experience of Andalusia in ehealth and big data --- Big data in health - IMI s HARMONY project, European Parliament, Brussels, 19 June 2018 Joaquín Dopazo Área de Bioinformática, Fundación Progreso
More informationBiotechnology Activities at the National Institutes of Health: Priorities and Trends. US-EU Task Force on Biotechnology Brussels, July, 2006
Biotechnology Activities at the s of Health: Priorities and Trends US-EU Task Force on Biotechnology Brussels, July, 2006 s of Health Office of of the the Director on on Aging on on Alcohol Abuse and and
More informationCOPE. FAQs CORPORATE ONCOLOGY PROGRAM FOR EMPLOYEES
COPE CORPORATE ONCOLOGY PROGRAM FOR EMPLOYEES FAQs This brochure addresses FAQ and is prepared solely for the German market. Local adjustments may be necessary. Please contact us if you require additional
More informationNIH Institutes and Areas of SBIR Research: (shown in order of FY 2010 Funding amounts)
NIH Institutes and Areas of SBIR Research: (shown in order of FY 2010 Funding amounts) 1. NCI (National Cancer Institute) cancer cause, prevention, detection, diagnosis, treatment and control 2. NIAID
More informationTOTAL CANCER CARE: CREATING PARTNERSHIPS TO ADDRESS PATIENT NEEDS
TOTAL CANCER CARE: CREATING PARTNERSHIPS TO ADDRESS PATIENT NEEDS William S. Dalton, PhD, MD CEO, M2Gen & Director, Personalized Medicine Institute, Moffitt Cancer Center JULY 15, 2013 MOFFITT CANCER CENTER
More informationBBMRI.at. Biobanking and BioMolecular resources Research Infrastructure Austria
THE AUSTRIAN NODE of the European Biobanking and BioMolecular resources Research Infrastructure BBMRI-ERIC Biobanking and BioMolecular resources Research Infrastructure Austria 3 BACKGROUND The impact
More informationCytomics in Action: Cytokine Network Cytometry
Cytomics in Action: Cytokine Network Cytometry Jonni S. Moore, Ph.D. Director, Clinical and Research Flow Cytometry and PathBioResource Associate Professor of Pathology & Laboratory Medicine University
More informationInterpreting Genome Data for Personalised Medicine. Professor Dame Janet Thornton EMBL-EBI
Interpreting Genome Data for Personalised Medicine Professor Dame Janet Thornton EMBL-EBI Deciphering a genome 3 billion bases 4 million variants 21,000 coding variants 10,000 non-synonymous variants 50-100
More informationStar Clusters in Spain
Star Clusters in Spain Center for Strategy and Competitiveness, CSC Stockholm School of Economics April 2011 This report presents the strongest regional clusters in Spain according to the European Cluster
More informationNordic Common Strengths and Future Potential in the Field of Personalised Medicine
Nordic Common Strengths and Future Potential in the Field of Personalised Medicine NOS-M Workshop 23rd November 2016 Stockholm Waterfront Johan Nilsson Coordinator Medicine and Health Swedish Research
More informationEATRIS accelerates translation of science into medical products that benefit patients and improve human health.
OUR PURPOSE EATRIS is a permanent EU biomedical research infrastructure. EATRIS accelerates translation of science into medical products that benefit patients and improve human health. OUR AIMS 1. Improving
More informationThe patient must address the treating physician directly if he/she has any questions or requires information regarding the test results.
Order Form 1. Ordering of the FoundationOne Service The FoundationOne Service comprises the genetic analysis of tumour tissue and the compilation of a comprehensive report on any mutations found in the
More informationMedicina personalizada en el sistema público de salud: la experiencia en Andalucía. Joaquín Dopazo
Medicina personalizada en el sistema público de salud: la experiencia en Andalucía Joaquín Dopazo Area de Bioinformática Clínica, Fundación Progreso y Salud, Functional Genomics Node, (INB-ELIXIR-es),
More informationTHE CELL BIOLOGY BEHIND THE ONCOGENIC PIP3 LIPIDS
WORKSHOPS CURRENT TRENDS IN BIOMEDICINE 2018 SEDE ANTONIO MACHADO BAEZA, SPAIN THE CELL BIOLOGY BEHIND THE ONCOGENIC PIP3 LIPIDS Baeza, Spain 15 th -17 th October 2018 Organized by: Richard A. Anderson
More informationSession: Innovative Technologies
Session: Innovative Technologies Abstract Title: Tissue Microarray Technology: New opportunity for Tissue Banks to contribute to Cancer Research and Diagnostics. Pasquale De Blasio Founding President of
More informationUsing Human Tissue in Translational Research and Clinical Trials
Using Human Tissue in Translational Research and Clinical Trials Dr Bridget S Wilkins NCRI Clinical Lead for Pathology Engagement (Consultant Histopathologist, St Thomas Hospital, London) Cellular and
More informationRare diseases in the 7th EU Framework Programme for Research and Technological Development
Rare diseases in the 7th EU Framework Programme for Research and Technological Development Manuel Hallen, MD Head of Unit Medical & Public Health Research DG Research European Commission 1 The role of
More informationAIT - Austrian Institute of Technology
BIOMARKER DISCOVERY, BIOINFORMATICS, AND BIOSENSOR DEVELOPMENT Technology Experience AIT Austrian Institute of Technology Low-Emission Transport AIT - Austrian Institute of Technology Energy Health & Bioresources
More informationREIG JOFRE TAKES OVER FROM ORYZON AND GETS CONTROL OF 100% OF GynEC -DX, A MOLECULAR DIAGNOSTIC TEST FOR EARLY DETECTION OF ENDOMETRIAL CANCER
REIG JOFRE TAKES OVER FROM ORYZON AND GETS CONTROL OF 100% OF GynEC -DX, A MOLECULAR DIAGNOSTIC TEST FOR EARLY DETECTION OF ENDOMETRIAL CANCER The transaction was conveyed by Reig Jofre taking control
More informationGenomics and personalised medicine
Genomics and personalised medicine Dr Tom Fowler, Deputy Chief Scientist & Director of Public Health WHO Symposium on the Future of Digital Health Systems in the European Region February 2019 About me
More informationEXPERT COLLECTION. Explore our leading medical review series
EXPERT COLLECTION Explore our leading medical review series Introducing the EXPERT COLLECTION The Taylor & Francis Expert Collection is the world s largest series of review journals in research, development,
More informationThe monthly variation of the Retail Trade Index at constant prices is 0.3% after adjusting for seasonal and calendar effects
1 October 2018 Retail Trade Indices (RTI). Base 2015 August 2018. Provisional data The monthly variation of the Retail Trade Index at constant prices is % after adjusting for seasonal and calendar effects
More informationOverview of comments received on IMI Advanced Therapies Concept Paper
Overview of comments received on IMI Advanced Therapies Concept Paper Stakeholder: CIBER-BBN CIBER is a public Biomedical Research Networking Centre designed to be a translational research centre with
More informationGenomic Research: Issues to Consider. IRB Brown Bag August 28, 2014 Sharon Aufox, MS, LGC
Genomic Research: Issues to Consider IRB Brown Bag August 28, 2014 Sharon Aufox, MS, LGC Outline Key genomic terms and concepts Issues in genomic research Consent models Types of findings Returning results
More informationNHS ENGLAND BOARD PAPER
NHS ENGLAND BOARD PAPER Paper: PB.30.03.2017/06 Title: Creating a genomic medicine service to lay the foundations to deliver personalised interventions and treatments Lead Director: Professor Sir Bruce
More informationBiotechnology Cluster of Andalusia
Introduction Andalucía BioRegión, the Map of agents Biotechnology and research in Andalusia Services 03 04 06 07 10 03 INTRODUCTION The Agency of Innovation and Development of Andalusia IDEA, attached
More informationClinical and Research Questions
Health Record: The Next Leap Forward John Glaser, PhD Vice President and CIO Partners HealthCare May 8, 2008 Clinical and Research Questions Research Why do some patients with asthma respond to steroid
More informationConference. Challenges and Opportunities of the Italian Hub of Population Biobanks (HIBP)
Conference Challenges and Opportunities of the Italian Hub of Population Biobanks (HIBP) March 9 th, 2012 Pocchiari Auditorium Viale Regina Elena, 299 00161 Rome, Italy Conference Challenges and opportunities
More informationEarly Patient Studies in Evolution. John Horkulak Executive Director, Eurasian External Study Operations Feb 23, 2015
Early Patient Studies in Evolution John Horkulak Executive Director, Eurasian External Study Operations Feb 23, 2015 Questions How are early phase studies evolving and why the push for studying patients
More informationNeurodegeneration and other neuroscience priorities
Potential future IMI Call topics About this document The following topics are under consideration for inclusion in future IMI Calls for proposals in the longer term. The discussions on these topics are
More informationOur website:
Biomedical Informatics Summer Internship Program (BMI SIP) The Department of Biomedical Informatics hosts an annual internship program each summer which provides high school, undergraduate, and graduate
More informationMaternal, Neonatal Health and Developmental Research Network SAMID (RD16/0021/0001)
Maternal, Neonatal Health and Developmental Research Network SAMID (RD16/0021/0001) Máximo Vento MD PhD National Coordinator RETICS RED SAMID Division of Neonatology University & Polytechnic Hospital la
More informationHeadline Verdana Bold
Headline Verdana Bold Proposal for a study report on Belgium as clinical trial location in Europe Belgium as clinical trial location in Europe Presentation of results for 2016 4 May 2018 Methodology of
More information